These findings suggest that TGFβ can cause changes in the tumor microenvironment essential for cancer progression, and, from an immunotherapeutic point of view, this role can be important in the development of cancer therapeutics [13, 14]. The gene discussed is TGFB1; the disease is neoplasm.